Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Даролутамид в дополнение к ГТ по сравнению с ГТ при метастатическом гормоночувствительном раке предстательной железы (ARANOTE)

3 сентября 2026 г. обновлено: Bayer

Рандомизированное двойное слепое плацебо-контролируемое исследование фазы 3 применения даролутамида в дополнение к андроген-депривационной терапии (АДТ) по сравнению с плацебо плюс АДТ у мужчин с метастатическим гормоночувствительным раком предстательной железы (мГРПЖ)

The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

Обзор исследования

Статус

Завершенный

Условия

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Действительный)

669

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

    • New South Wales
      • Kingswood, New South Wales, Австралия, 2747
        • Nepean Hospital
      • St Leonards, New South Wales, Австралия, 2065
        • Northern Cancer Institute
      • Sydney, New South Wales, Австралия, 2109
        • Macquarie University Hospital - Oncology Department
    • South Australia
      • Adelaide, South Australia, Австралия, 5000
        • Cancer Research South Australia
    • Victoria
      • Frankston, Victoria, Австралия, 3199
        • Peninsula Oncology Centre
      • Heidelberg, Victoria, Австралия, 3084
        • Austin Health
      • Rio de Janeiro, Бразилия, 22793-080
        • Instituto COI de Educação e Pesquisa
    • Estado de Bahia
      • Salvador, Estado de Bahia, Бразилия, 41950-640
        • Assistência Multidisciplinar em Oncologia (AMO)
    • Goiás
      • Goiânia, Goiás, Бразилия, 74605-070
        • Hosp. Araujo Jorge da Associação de Combate ao Câncer
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Бразилия, 30130-100
        • Hospital da Universidade Federal de Minas Gerais
      • Belo Horizonte, Minas Gerais, Бразилия, 30150-270
        • Cetus Oncologia Hospital Dia
    • Paraná
      • Curitiba, Paraná, Бразилия, 81520-060
        • Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Бразилия, 59040-000
        • Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica
    • Rio Grande do Sul
      • Pelotas, Rio Grande do Sul, Бразилия, 96020-080
        • Unidade de Pesquisas Clinicas em Oncologia
      • Porto Alegre, Rio Grande do Sul, Бразилия, 90850-170
        • Hospital Mae de Deus
      • Porto Alegre, Rio Grande do Sul, Бразилия, 91350-280
        • FZ Pesquisa e Servicos em Cardiologia | Porto Alegre, Brazil
      • Porto Alegre, Rio Grande do Sul, Бразилия, 90020-090
        • Santa Casa de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia
    • São Paulo
      • Barretos/SP, São Paulo, Бразилия, 14784-400
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • São José do Rio Preto, São Paulo, Бразилия, 15090-000
        • Hospital de Base | Funfarme - Centro Integrado de Pesquisa - Cardiologia
      • São Paulo, São Paulo, Бразилия, 03102-002
        • IBCC - Instituto Brasileiro de Controle do Cancer
      • São Paulo, São Paulo, Бразилия, 01243-020
        • Urobrasil
      • São Paulo, São Paulo, Бразилия, 04039-004
        • Inst. de Assistência Médica ao Sérvidor Público Estadual
      • Chandigarh, Индия, 160012
        • Post Graduate Institute of Medical Education and Research
      • Kolkata, Индия, 700156
        • Tata Medical Center
      • Nashik, Индия, 422009
        • Apex Wellness Hospital
      • New Delhi, Индия, 110 085
        • Rajiv Gandhi Cancer Institute & Research Centre
    • Andhra Pradesh
      • Visakhapatnam, Andhra Pradesh, Индия, 530017
        • Mahatma Gandhi Cancer Hospital & Research Institute
    • Gujarat
      • Ahmedabad, Gujarat, Индия, 380016
        • The Gujarat Cancer & Research Institute
      • Ahmedabad, Gujarat, Индия, 380060
        • HCG Cancer Centre - Ahmedabad
      • Vadodara, Gujarat, Индия, 390007
        • Cancer Care Clinic - Vadodara
    • Karnataka
      • Belagavi, Karnataka, Индия, 590010
        • K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
      • Bengaluru, Karnataka, Индия, 560027
        • Healthcare Global Enterprises Ltd
    • Kerala
      • Kochi, Kerala, Индия, 682 041
        • Amrita Institute of Medical Sciences
      • Thiruvananthapuram, Kerala, Индия, 695011
        • Regional Cancer Centre - Thiruvananthapuram
    • Maharashtra
      • Chhatrapati Sambhajinagar, Maharashtra, Индия, 431001
        • Marathwada Regional Cancer Centre and Research Institute
      • Mumbai, Maharashtra, Индия, 400026
        • Jaslok Hospital and Research Centre
      • Nashik, Maharashtra, Индия, 422004
        • Curie Manavata Cancer Centre
      • Pune, Maharashtra, Индия, 411001
        • Jehangir Hospital
    • Odisha
      • Bhubaneswar, Odisha, Индия, 751019
        • All India Institute of Medical Sciences
      • Bhubaneswar, Odisha, Индия, 751007
        • Sparsh Hospital & Critical Care
    • Puducherry
      • Gorimedu, Puducherry, Индия, 605006
        • Jawaharlal Institute Of Postgraduate Medical Education and R
    • Punjab
      • Ludhiana, Punjab, Индия, 141008
        • Christian Medical Center & Hospital
    • Rajasthan
      • Jaipur, Rajasthan, Индия, 302017
        • Sawami Man Singh (SMS) Medical College & Attached Hospitals
    • Tamil Nadu
      • Madurai, Tamil Nadu, Индия, 625020
        • Apollo Speciality Hospitals
      • Madurai, Tamil Nadu, Индия, 625107
        • Meenakshi Mission Hospital & Research Centre
      • Barcelona, Испания, 08025
        • Fundacio Puigvert | Urologia
      • Barcelona, Испания, 08208
        • Parc Tauli Hospital Universitari | Oncologia
      • Cáceres, Испания, 10003
        • Hospital San Pedro De Alcantara | Oncologia
      • Málaga, Испания, 20910
        • Hospital Universitario Virgen De La Victoria | Urologia
      • Seville, Испания, 41013
        • Hospital Universitario Virgen Del Rocio S.L. | Urologia
    • Madrid
      • Alcorcón, Madrid, Испания, 28922
        • Hospital Universitario Fundacion Alcorcon | Urologia
    • Ontario
      • Burlington, Ontario, Канада, L7N 3V2
        • G. Kenneth Jansz Medicine Professional Corporation
    • Quebec
      • Montreal, Quebec, Канада, H2X 0A9
        • Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
      • Beijing, Китай, 100142
        • Beijing Cancer Hospital
      • Beijing, Китай, 100083
        • Peking University Third Hospital
      • Beijing, Китай, 100000
        • Cancer Hospital, Chinese Academy of Medical Sciences
    • Anhui
      • Hefei City, Anhui Province, Anhui, Китай, 230031
        • Anhui Provincial Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Китай, 100730
        • Beijing Hospital
    • Guangdong
      • Guangzhou, Guangdong, Китай, 510000
        • Sun Yat-sen University Cancer Center
      • Guangzhou, Guangdong, Китай, 510180
        • Guangzhou First People Hospital
      • Shenzhen, Guangdong, Китай, 518172
        • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
    • Hubei
      • Wuhan, Hubei, Китай, 430030
        • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
      • Wuhan, Hubei, Китай, 430079
        • Hubei Cancer Hospital
      • Wuhan, Hubei, Китай, 430071
        • Zhongnan hospital ,Wuhan University
    • Hunan
      • Changsha, Hunan, Китай, 410013
        • Hunan Cancer Hospital - Oncology Department
    • Jiangsu
      • Nanjing, Jiangsu, Китай, 210008
        • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
      • Nantong, Jiangsu, Китай, 226361
        • Nantong tumor hospital
      • Suzhou, Jiangsu, Китай, 215004
        • The 2nd Affiliated Hospital of Soochow University
    • Jilin
      • Changchun, Jilin, Китай, 130021
        • 1st Hospital of Jilin University
    • Liaoning
      • Shengyang, Liaoning, Китай, 110042
        • Liaoning Cancer Hospital and Institute
    • Shandong
      • Yantai, Shandong, Китай, 264000
        • Yantai Yuhuangding Hospital
    • Shanxi
      • Xi’an, Shanxi, Китай, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
    • Sichuan
      • Chengdu, Sichuan, Китай, 610072
        • SichuanAcademyofMedicalSciences&SichuanProvincialPeople'sHos
      • Chengdu, Sichuan, Китай, MISSING
        • Sichuan University West China Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Китай, 310000
        • The 1st Affiliated Hospital of Zhejiang University
      • Hangzhou, Zhejiang, Китай, 310014
        • ZheJiang Provincial People's Hospital
      • Ningbo, Zhejiang, Китай, 315010
        • Ningbo First Hospital
      • Wenzhou, Zhejiang, Китай, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Daugavpils, Латвия, LV-5417
        • Daugavpils Regional Hospital
      • Riga, Латвия, 1038
        • RAKUS Hospital Gailezers
      • Riga, Латвия, LV-1001
        • URO Ltd.
      • Riga, Латвия, LV-1002
        • P. Stradins Clinical University Hospital
      • Valmiera, Латвия, LV-4201
        • Vidzemes Hospital
      • Kaunas, Литва, LT-50009
        • The Hospital of Lithuanian University of Health SciencesLUHS
      • Klaipėda, Литва, LT-92288
        • PI Klaipedos University Hospital
      • Vilnius, Литва, LT-08660
        • National Cancer Institute
      • Vilnius, Литва, LT-08661
        • Vilnius University Hospital Santaros Klinikos
    • Bay of Plenty
      • Tauranga, Bay of Plenty, Новая Зеландия, 3112
        • Tauranga Urology Research Limited
    • Canterbury
      • Christchurch, Canterbury, Новая Зеландия, 8013
        • Canterbury Urology Research Trust
    • Waikato Region
      • Hamilton, Waikato Region, Новая Зеландия, 3240
        • Waikato Hospital
      • Lima, Перу, LIMA 11
        • Hospital Militar Luis Arias Schreiber
      • Lima, Перу, LIMA 27
        • Clínica El Golf
    • Lima region
      • San Isidro, Lima region, Перу, 15036
        • Aliada
      • Santiago de Surco, Lima region, Перу, 15033
        • Hospital Guillermo Almenara Irigoyen
      • Arkhangelsk, Россия, 163045
        • Arkhangelsk Clinical Oncology Dispensary
      • Chelyabinsk, Россия, 454087
        • Chelyabinsk Regional Oncology Dispensary
      • Chelyabinsk, Россия, 454048
        • Ltd "EVIMED"
      • Ivanovo, Россия, 153040
        • Ivanovo Regional Oncology Dispensary
      • Kazan', Россия, 420029
        • Republican Clinical Oncology Dispensary Kazan
      • Moscow, Россия, 117997
        • Research Centre of X-ray and Radiology
      • Nizhny Novgorod, Россия, 603109
        • Volga District Med Center FMBA
      • Novosibirsk, Россия, 630099
        • LLC Reafan
      • Novosibirsk, Россия, 630099
        • Medical Center "Avicenna"
      • Omsk, Россия, 644013
        • Clinical Oncological Dispensary of Omsk Region
      • Saint Petersburg, Россия, 196006
        • AV Medical Group
      • Saint Petersburg, Россия, 197758
        • Russian Scientific Radiology and Surgery Technologies Center
      • Saint Petersburg, Россия, 197758
        • Scientific Research Instutute of Oncology n.a. N.N. Petrov
      • Tyumen, Россия, 625041
        • Multi-Field Clinical Medical Center "Medical City"
      • Ufa, Россия, 450054
        • Republican Clinical Oncology Dispensary
      • Vologda, Россия, 160022
        • Vologda Regional Hospital
      • Yekaterinburg, Россия, 620102
        • Sverdlovsk Regional Clinical Hospital #1
      • Changhua, Тайвань, 50006
        • Changhua Christian Hospital
      • Taichung, Тайвань, 40705
        • Taichung Veterans General Hospital
      • Tainan, Тайвань, 704
        • National Cheng Kung University Hospital
      • Taipei, Тайвань, 11217
        • Taipei Veterans General Hospital
    • Kaohsiung
      • Kaohsiung City, Kaohsiung, Тайвань, 807377
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Cherkasy, Украина, 18009
        • CNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of the Cherkasy Regional Council"
      • Dnipro, Украина, 49102
        • City Dnipropetrovsk Multi- field Clinical Hosp. 4 DSMA
      • Kyiv, Украина, 4107
        • Kyiv Regional Oncological Dispensary
      • Kyiv, Украина, 02660
        • Kyiv City Hospital #3 - Department of Urology
      • Santiago, Чили, 7510032
        • Oncovida
      • Santiago, Чили
        • UROMED
      • Santiago, Чили, TBC
        • Hospital Clínico de la Pontificia Univ. Católica de Chile
      • Santiago, Чили, 7500921
        • Fundación Arturo López Perez
    • Araucania
      • Temuco, Araucania, Чили, 4781156
        • Centro de Investigación Clínica del Sur
    • Santiago Metropolitan
      • Providencia, Santiago Metropolitan, Чили, 7500653
        • Centro de Estudios Clínicos SAGA SpA
    • Valparaiso
      • Viña del Mar, Valparaiso, Чили, 2520598
        • OncoCentro
      • Cape Town, Южная Африка, 7570
        • Cape Town Oncology Trials
    • Eastern Cape
      • Port Elizabeth, Eastern Cape, Южная Африка, 6045
        • Cancercare Langenhoven
    • Gauteng
      • Johannesburg, Gauteng, Южная Африка, 1475
        • East Rand Medical Research Unit
      • Pretoria, Gauteng, Южная Африка, 2
        • University of Pretoria, Clinical Research Unit

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Мужской

Описание

Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of prostate
  • Metastatic disease
  • Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but not earlier than 12 weeks before randomization
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
  • Adequate bone marrow, liver and renal function

Exclusion Criteria:

  • Prior treatment with: LHRH agonist/antagonists except neoadjuvant and /or adjuvant therapy; Second-generation androgen receptor (AR) inhibitors such as enzalutamide, darolutamide, apalutamide or other investigational AR inhibitors; Cytochrome P17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as anti-cancer treatment for prostate cancer; Chemotherapy including docetaxel or immunotherapy for prostate cancer; Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days prior to randomization; Radiopharmaceuticals; Any other anti-cancer treatment for prostate cancer, excluding local therapies and ADT.
  • Treatment with radiotherapy within 2 weeks before randomization
  • Contraindication to iodinated CT and gadolinium chelate MRI intravenous contrast agent(s)
  • Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)
  • Uncontrolled hypertension as indicated by a resting systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite medical management
  • A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of study drug
  • Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization
  • Inability to swallow oral medications

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Darolutamide+ADT

Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy

Coated tablet, oral administration

Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy

Плацебо Компаратор: Placebo+ADT

Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy

Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy

Coated tablet matching Darolutamide in appearance, oral administration

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Radiological Progression-free Survival (rPFS) Assessed by Central Review
Временное ограничение: From randomization to the date when 222 rPFS events were observed, approximately 36 months

rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria.

From randomization to the date when 222 rPFS events were observed, approximately 36 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Overall Survival (OS)
Временное ограничение: From randomization to the final analysis date, approximately 47 months

Time from the date of randomization to the date of death from any cause.

From randomization to the final analysis date, approximately 47 months
Time to Castration-Resistant Prostate Cancer (CRPC)
Временное ограничение: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first).

From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to Initiation of Subsequent Anti-cancer Therapy
Временное ограничение: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer.

From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to PSA Progression
Временное ограничение: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level <0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels <0.50 ng/mL is requested at initial assessment.

From randomization to the date when 222 rPFS events were observed, approximately 36 months
PSA Undetectable Rates (<0.2 ng/mL)
Временное ограничение: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values <0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline.

From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to Pain Progression
Временное ограничение: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale [WPS]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS >0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization.

From randomization to the date when 222 rPFS events were observed, approximately 36 months
Number of Participants With Adverse Events as a Measure of Safety
Временное ограничение: From start of study drug administration until 30 days after the last administration

An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug.

From start of study drug administration until 30 days after the last administration

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Соавторы

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

23 февраля 2021 г.

Первичное завершение (Действительный)

7 июня 2024 г.

Завершение исследования (Действительный)

23 января 2026 г.

Даты регистрации исследования

Первый отправленный

29 января 2021 г.

Впервые представлено, что соответствует критериям контроля качества

29 января 2021 г.

Первый опубликованный (Действительный)

3 февраля 2021 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

29 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

3 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • 21140
  • 2020-003093-48 (Номер EudraCT)
  • 2022-502244-12-00 (Другой идентификатор: CTIS (EU))

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Описание плана IPD

Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .